New hope for kids with kidney disease: rituximab cuts relapse risk
NCT ID NCT07049172
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 28 times
Summary
This study looked at whether rituximab, a medication that targets certain immune cells, can help children with a challenging form of nephrotic syndrome (a kidney condition) have fewer relapses. 91 children were randomly assigned to receive either rituximab or another drug called tacrolimus, along with special nursing care. The researchers tracked how well each treatment worked over 6 months, focusing on relapse rates and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wuhan Children's Hospital
Wuhan, Hubei, 430015, China
Conditions
Explore the condition pages connected to this study.